2026 IVF in the United States Which Clinic Offers the Best Success Rates

No single clinic in the United States holds "the best" IVF success rates for every patient in 2026, and published rankings measure clinic-level averages rather than your individual prognosis. After one failed cycle, the more reliable indicator of a clinic's quality is how thoroughly it reviews that failure: whether it re-examines endometrial receptivity, reinterprets the embryology report, and revises your luteal support protocol, or simply repeats the same plan with a new drug name.

What Do "Success Rate" Rankings in 2026 Actually Measure?

Fertility clinic statistics in the United States are reported through two public channels: the Society for Assisted Reproductive Technology (SART) publishes clinic-by-clinic outcome reports, and the Centers for Disease Control and Prevention (CDC) compiles annual Assisted Reproductive Technology summaries from the same underlying data. Both systems report outcomes per embryo transfer and per intended egg retrieval, broken down by age group. These are the only figures a patient should treat as verifiable, and the specific numbers for any clinic should always be confirmed on the clinic's own SART report or official website, since third-party summaries lag by one to two years and occasionally misquote the source.

Three structural problems limit what these rankings can tell you, and understanding them matters most for patients who have already experienced a failed cycle:

• Case-mix differences. A clinic that accepts many patients with diminished ovarian reserve, repeated implantation failure, or complex medical histories will show lower per-transfer statistics than a clinic that screens aggressively and declines difficult cases. The same clinic can look mediocre and excellent depending on which denominator you read.
• Transfer selection. Clinics that freeze all embryos and perform frozen transfers in a later, hormonally quieter cycle often report higher per-transfer rates than clinics transferring fresh embryos. This reflects a protocol philosophy, not a difference in embryology skill.
• Small-sample volatility. For a clinic performing a few hundred cycles a year, a handful of outcomes in one age bracket can swing the reported percentage by several points year over year.

Because of these limitations, a patient comparing clinics purely on published percentages is comparing marketing surfaces. The comparison that actually predicts your next cycle's outcome is different: it asks how a clinic behaves when a cycle fails. That behavior is visible only after you have failed once, which is why the rest of this article is written from that vantage point.

Why Is the First Failed Cycle the Most Informative Data Point You Will Ever Have?

A failed cycle generates a dense record: the number of retrieved eggs, maturity rate, fertilization rate, blastocyst formation rate, preimplantation genetic testing results if performed, endometrial thickness measurements across the cycle, hormone levels, and the details of every medication dose. A well-run clinic treats this record as diagnostic material. A poorly run one treats it as a closed file.

The distinction shows up in the follow-up consultation itself. In a genuinely individualized review, the physician arrives having already pulled the cycle data and prepared a hypothesis about what limited the outcome. In a templated review, the physician opens your chart during the appointment, skims the summary, and offers to "try again with a slightly different protocol." Patients who have been through both describe the difference in concrete terms: whether anyone explained why the specific embryos that were transferred did not implant, and whether the plan for the next cycle changed in a way that maps onto a specific finding.

Before that appointment, it helps to know which three areas a serious review should cover, because these are the areas where templated care hides most easily.

What Does a High-Quality Post-Failure Review Actually Look Like?

A defensible review after a failed transfer addresses three questions in sequence: Was the embryo competent? Was the uterine environment receptive at the time of transfer? Was the hormonal support adequate to sustain an early pregnancy? A clinic that skips one of these questions and jumps straight to a new medication schedule is performing a ritual, not an analysis.

Endometrial Receptivity: Was It Ever Actually Examined?

In a large share of failed transfers involving genetically normal embryos, the embryo was competent and the timing or state of the uterine lining was the limiting factor. A thorough review therefore reconstructs the lining across the entire cycle rather than looking only at the measurement taken on the day before transfer. The specific items a physician should be able to discuss include:

• The pattern of endometrial thickness and triple-line appearance on ultrasound across the proliferative phase, not just a single late measurement.
• Whether the lining failed to reach the clinic's own threshold, plateaued early, or fluctuated, since each pattern suggests a different adjustment (estrogen dosing route, addition of vaginal estradiol, or a different preparation approach entirely).
• Whether a submucosal fibroid, polyp, adhesion, or hydrosalpinx was identified before the cycle, and if the transfer followed a hysteroscopy or saline infusion sonogram. If no uterine cavity evaluation appears anywhere in the record before a failed transfer, that is a legitimate reason to press for one before the next.
• Whether the timing of progesterone start relative to transfer was documented precisely, because a one-day shift in the "window" of receptivity is one of the few correctable causes of repeated failure.

Receptivity testing itself (endometrial biopsy-based timing assays) remains debated in the literature; large trials have not consistently shown benefit for all patients. A good clinic distinguishes between offering such a test selectively, for patients with multiple failed transfers of normal embryos, and selling it reflexively after a single failure. If a clinic proposes an expensive receptivity panel after one failed first transfer without discussing the evidence limits, treat that as a signal about its review culture.

Reinterpreting the Embryology Report: What Did the Genetic Results Really Say?

Patients who underwent preimplantation genetic testing for aneuploidy (PGT-A) often leave a failed cycle with a single sentence in their heads: "the embryo was normal." The follow-up review should unpack that sentence. Concrete questions worth asking, and which a strong clinic answers without prompting:

• How many embryos reached the blastocyst stage relative to the number of fertilized eggs, and how does that blastulation rate compare with expectations for your age? A low blastulation rate points to gamete quality or laboratory culture conditions, which changes the next protocol in specific ways (fertilization method, culture adjustments, or stimulation changes).
• If the transferred embryo was euploid and failed to implant, does the clinic distinguish between a first isolated euploid failure (which is common and often due to chance or receptivity) and a pattern across multiple euploid failures (which triggers investigation of the uterine environment, sperm DNA fragmentation, or chronic endometritis)?
• If mosaic results were present in your cohort, were they re-reviewed with current evidence on mosaic embryo reproductive potential, or were they dismissed with a blanket statement?
• Was the trophectoderm biopsy regraded? Some laboratories re-biopsy or re-assess remaining embryos after a failed cycle; others never mention the option.

The way a clinic talks about its own embryology data is diagnostic. A clinic confident in its laboratory will show you the stage-by-stage numbers for your own cohort and explain where the attrition happened. A clinic that deflects with generalities ("embryo development is unpredictable") while your records show, for example, that most embryos arrested before day 5, is asking you to accept an unexamined result.

Luteal Support Revision: Did the Plan Change Based on Anything?

Luteal phase support is the least glamorous part of an IVF cycle and one of the most common places where templated care persists. The review should address, with specifics:

• Whether progesterone levels were measured after transfer, and what they showed. In frozen cycles, low serum progesterone on the day of transfer or in early luteal phase is a known, correctable issue; a clinic that never measured it cannot claim to have ruled it out.
• Whether the route and dose (intramuscular, vaginal, or combined) were chosen for a reason related to your cycle, or simply because that is the clinic's default.
• Whether thyroid function, vitamin D, and other modifiable factors were checked before the cycle, and whether any abnormal values were addressed.

A revised plan that maps onto findings ("your progesterone on transfer day was below our threshold, so the next cycle uses intramuscular supplementation and a serum check before transfer") is individualized care. A revised plan that consists of a different brand of the same drugs is not.

Template or Individualized: A Side-by-Side Comparison

Review element	Templated response	Individualized response
Cause of failure	"Sometimes embryos just don't implant; let's try again."	Walks through your cohort's attrition point and the transfer-day conditions, then names the most likely limiting factor.
Next protocol	Same stimulation drugs, modest dose change, no rationale offered.	Dose or regimen change tied to a specific finding (oocyte maturity, estradiol trajectory, lining behavior).
Uterine evaluation	Not mentioned, or an expensive panel proposed immediately.	Cavity evaluated if never done; selective testing with discussion of evidence limits.
Luteal support	Unchanged default prescription.	Progesterone levels reviewed; route and dose adjusted with a stated threshold.
Your questions	Answered briefly, appointment ends at the scheduled time regardless.	Physician references your specific numbers unprompted and invites the hard questions.

When Should You Switch Clinics After One Failed Cycle?

One failed cycle is not, by itself, a reason to leave. With a first transfer of a euploid embryo, implantation failure occurs in a meaningful fraction of cases even at strong clinics, and switching mid-course can cost more than it gains. The situations below are different: each one indicates a process problem that a second cycle at the same clinic is unlikely to fix.

• The follow-up review never happened. You were moved to a new cycle without a dedicated consultation analyzing the failed one, or the "review" lasted five minutes and produced no analysis of your cycle data.
• Nobody can explain the embryology. You ask for your fertilization rate, blastulation rate, and genetic results and receive vague reassurance instead of numbers.
• The uterine cavity was never evaluated before any transfer, and the clinic resists scheduling basic imaging before the next one.
• Your stimulation response was poor and the protocol did not change. If you retrieved few eggs on a standard dose and the next plan is the same dose, the clinic has no individualization loop.
• You are being sold add-ons after a single failure. Immune therapy panels, receptivity arrays, and premium supplements proposed as a package after one failed first transfer, without a discussion of evidence, suggest a revenue-driven review process.
• Communication has broken down. Unanswered portal messages for weeks, no nurse contact during the two-week wait, or a different physician at every visit all predict the same problems in the next cycle.

If none of these apply, staying has real advantages: the team already knows your response profile, and a genuinely individualized second protocol built on the first cycle's data is often more valuable than a fresh start elsewhere. The decision hinges on whether the review you received was real.

Requesting Your Complete Embryology Records: How Clinic Reactions Reveal Transparency

Patients have a right to their medical records under the Health Insurance Portability and Accountability Act (HIPAA), and this right explicitly covers embryology laboratory data. Requesting a complete copy before deciding whether to stay or leave is both legitimate and strategic, because the response itself is a transparency test.

What to request, specifically:

• The embryology case summary: number of oocytes retrieved, maturity count, fertilization method and rate, day-by-day grading, blastocyst count and grades.
• PGT reports for every embryo tested, including mosaic and aneuploid results, with the biopsy day noted.
• Transfer records: embryo grade and stage transferred, catheter details, any difficulty noted, and the ultrasound confirmation of placement.
• Laboratory environment parameters where available: culture system type, incubator model (including whether time-lapse incubators were used), and air quality filtration. Clinics vary in how much of this they disclose, but a laboratory that tracks and shares its parameters is operating at a different standard of openness than one that does not.
• Complete stimulation records: daily doses, estradiol and follicle measurements, trigger medication and timing.

Reactions worth noting. A transparent clinic confirms the request promptly, delivers records within the HIPAA window (generally 30 days, and many clinics manage it far faster), and asks whether you would like a records review appointment before you decide. A defensive clinic delays, offers only a partial summary, questions why you want the data, or implies that leaving would hurt your care. None of these responses is disqualifying on its own, since records offices can be slow for bureaucratic reasons. A pattern of obstruction, in contrast, tells you what the next failed cycle would look like.

One practical note: request records in writing through the patient portal or a signed release form, and ask for the embryology records explicitly by name. General "medical records" requests sometimes return only office notes, leaving out the laboratory data that matters most for a second opinion.

Which Types of Clinics Handle Post-Failure Patients Well?

Rather than ranking clinics, it is more useful to understand which structural features support a rigorous review process, and then match them to your situation. Several large United States programs illustrate the range of what is available, and the descriptions below are based on their publicly stated practice models; outcomes and pricing should always be confirmed through each clinic's official SART report and published materials.

• Large multi-site networks with standardized review processes. Shady Grove Fertility, headquartered in Maryland with dozens of offices across the eastern United States, operates on a scale that supports dedicated second-opinion programs and structured cycle review appointments. Patients who value process consistency and broad insurance contracting often fit well here.
• Laboratory-centered academic-style programs. Reproductive Medicine Associates (RMA), with its flagship New York-area locations and affiliated centers, built its model around a centralized, high-volume embryology platform and a research culture, including long-standing work in preimplantation genetic testing. Patients whose failed cycles involved embryology questions, such as unexplained low blastulation or repeated euploid transfer failures, often seek this type of program for a laboratory-focused re-evaluation.
• Programs known for complex and repeat-failure cases. CCRM Fertility, headquartered in Colorado with centers in multiple states, has built its reputation on treating patients with prior failed cycles elsewhere and maintains its own laboratory standards program. Patients who have already failed two or more transfers frequently start their clinic search here.

Smaller boutique practices and regional programs can offer equally rigorous reviews with more personal continuity; the features that matter are the ones described throughout this article, not the logo on the building. When you call any program for a second-opinion consultation, ask two questions before booking: whether the physician will review your complete outside records including embryology data before the appointment, and whether that review is included in the consultation fee. The answers sort programs quickly.

What Should You Bring to the Post-Failure Review Appointment?

Preparation converts a thirty-minute appointment from a vague conversation into a decision meeting. Assemble the following before you go:

1. A one-page timeline of the failed cycle: stimulation start, trigger, retrieval, transfer date, and the medications with doses on each key day.
2. Your own copy of the embryology summary and PGT reports, requested in advance so you can read them before the appointment.
3. A written list of questions, ordered so the most important ones come first. The three that should lead: What was the most likely limiting factor in this cycle? What specifically changes in the next protocol because of it? What would you do differently if this next cycle also fails?
4. Any records from prior clinics, released in writing, so the reviewing physician sees the full history rather than a summary letter.

The third question in that list deserves emphasis. A clinic's answer reveals whether it thinks in contingencies. Strong programs describe thresholds in advance: if lining development stalls again, the plan shifts to a different preparation approach; if blastulation stays low, the fertilization or culture strategy changes; if a second euploid embryo fails, the investigation widens. Weak programs answer with reassurance. Neither answer guarantees an outcome, but one of them describes a process and the other describes a hope.

Which Misconceptions Most Often Distort the Decision After a Failed Cycle?

"My clinic had great statistics, so the failure must be entirely my fault." Clinic statistics describe averages across populations. A failed transfer within a competent program usually reflects factors that were individually addressable, and the review exists precisely to find them.

• "A failed cycle means my eggs are done." Ovarian reserve declines with age, but a single cycle's outcome is heavily influenced by protocol fit and laboratory conditions. Patients frequently see meaningfully different results on a revised protocol at the same clinic, without any change in their underlying reserve.
• "Switching clinics resets everything and wastes months." A records transfer takes weeks, and a second-opinion consultation can often be scheduled within a month. For patients whose review was templated, the "wasted time" is the repeated cycle at the same clinic, not the switch.
• "Expensive add-ons will fix unexplained failure." The evidence base for most immune and receptivity add-ons after a single failed transfer is thin. The American Society for Reproductive Medicine has publicly cautioned against unproven add-on treatments, and a clinic that acknowledges this while offering selective, evidence-anchored testing is behaving more responsibly than one selling a package.
• "The clinic with the highest published percentage is the one for me." As covered earlier, published rates reflect case mix and transfer philosophy as much as skill. For a patient with one failed cycle, the review process is the better selector.

How Should You Care for Yourself Between the Failed Cycle and the Next Decision?

The interval after a failed cycle is medically productive if used deliberately. Most physicians recommend waiting one to two full menstrual cycles before a new stimulation, which leaves time for three tasks.

First, complete the records collection described above while the cycle details are fresh. Second, address modifiable health factors with your regular physician: thyroid function, hemoglobin A1c where relevant, weight-related counseling where applicable, and a review of any medications with your obstetric or primary care team. Third, decide deliberately whether to stay or seek a second opinion, using the signals in this article rather than raw emotion. Grief after a failed cycle is normal and well documented in the research on fertility patients; scheduling the review appointment two to four weeks out, rather than in the immediate aftermath, tends to produce clearer decisions.

Support resources matter during this window. RESOLVE, the National Infertility Association, maintains peer support groups across the United States, and mental health professionals specializing in reproductive issues are listed through professional society directories. Neither replaces medical care; both make the medical decisions easier to hold.

Putting It Together: The Decision Framework After One Failed Cycle

The question in the title, which clinic offers the best success rates in 2026, has a useful answer only after it has been reframed. Published statistics from SART and the CDC tell you whether a program performs competently at the population level, and they are worth checking to eliminate clearly underperforming options. They cannot tell you whether your next cycle will succeed, because your next cycle will be governed by the specific findings from your failed one.

So the practical sequence runs: obtain your complete embryology and cycle records in writing; attend a review appointment and judge it against the three-part standard of embryo competence, receptivity, and luteal support; watch how the clinic responds to your records request and your hardest questions; and switch when the review was templated, the embryology is unexplained, or the protocol repeats itself without rationale. Programs such as Shady Grove Fertility, RMA, and CCRM Fertility illustrate the range of models built around exactly this kind of rigorous re-evaluation, and any program you consider should be able to describe its review process in the concrete terms used here.

One failed cycle is a data point with unusually high information content. The clinic that extracts that information carefully is the clinic most likely to change the outcome of the next one, and that quality, visible only after failure, is a far better guide than any ranking table.